17 К.В. Меньшиков А.В. Султанбаев К.Т. Ахметгареева Д.О. Липатов 2021 2021-06-18 10.26442/18151434.2021.1.200785 Hepatocellular carcinoma (HCC) or liver cancer is the most common primary malignant tumor of the liver, which is characterized on the first place by a poor prognosis. HCC was diagnosed in 92 patients (62.6%) in 2019 and the period from January to April 2020 in the Republic of Bashkortostan, and among them, 68.47% had stage IV cancer. International professional guidelines sug-gest screening for early HCC detection. Systemic drug therapy is the treatment of choice for inoperable HCC according to profes-sional guidelines. Inhibition of the VEGF pathway is one of the current methods of therapy for advanced HCC. Lenvatinib is a ty-rosine kinase inhibitor for the treatment of advanced HCC that is not subject to local interventions. This article provides a desc-ription of a clinical case of successful treatment of a 67-year-old patient with advanced hepatocellular carcinoma. He was appointed for targeted therapy with lenvatinib for HCC that was not subject to local interventions, which led to long-term stabili-zation. There was a positive trend in the patient's condition from the first weeks of therapy. The working capacity was restored. The therapy showed a satisfactory tolerability profile. © 2021 Biemdas Academic Publishers. All rights reserved. https://repo.bashgmu.ru/publication/1841 https://repo.bashgmu.ru/files/2013